Crinetics Pharmaceuticals (CRNX) Cash & Equivalents (2017 - 2026)

Crinetics Pharmaceuticals' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $114.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 20.91% year-over-year to $114.3 million; the TTM figure through Mar 2026 stood at $114.3 million (up 20.91% YoY), while the FY2025 annual figure was $101.5 million, down 61.62% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $114.3 million, up from $101.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $395.9 million in Q1 2024, with the low at $30.9 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $101.5 million (2025), against an average of $135.6 million.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents sank 83.76% in 2022, then surged 861.14% in 2024.
• Crinetics Pharmaceuticals' Cash & Equivalents stood at $32.7 million in 2022, then soared by 68.02% to $54.9 million in 2023, then surged by 381.89% to $264.5 million in 2024, then plunged by 61.62% to $101.5 million in 2025, then climbed by 12.61% to $114.3 million in 2026.
• Business Quant data shows CRNX's Cash & Equivalents at $114.3 million in Q1 2026, $101.5 million in Q4 2025, and $110.9 million in Q3 2025.